Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q1 2026 · 10-Q
Revenue—
Net Income-$15.77M-$15.77MN/M vs Q1 2025 EPS Diluted-$1.20-$1.20N/M vs Q1 2025 Operating Income-$14,855,000N/M Operating Cash Flow-$10,864,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
ended Mar 31, 2026 · filed May 7, 2026 · 37 d after period end